iPierian Acquired by Bristol-Myers Squib in a $725m Deal

Bristol-Myers Squib (BMS) announced the acquisition of biotechnology compsny iPierian in a $725M deal aimed at further strengthening BMS’s position in Tau biology and neurodegenerative diseases. iPierian is applying stem cell technologies to help treat neurodegenerative diseases, in particular, Alzheimer’s disease, spinal muscular atrophy, and ALS. Their lead compound, IPN007, is a preclinical stage monoclonal antibody that is expected to enter Phase I clinical trials in 2015 for progressive supranuclear palsy (PSP), a rapidly progressing neurodegenerative disorder associated with Tau dysfunction. In the future, development plans for the drug could extend to other Tauopathies such as frontotemporal dementia and Alzheimer’s disease.

Bristol-Myers Squib (BMS) announced the acquisition of biotechnology compsny iPierian in a $725M deal aimed at further strengthening BMS’s position in Tau biology and neurodegenerative diseases. iPierian is applying stem cell technologies to help treat neurodegenerative diseases, in particular, Alzheimer’s disease, spinal muscular atrophy, and ALS. Their lead compound, IPN007, is a preclinical stage monoclonal antibody that is expected to enter Phase I clinical trials in 2015 for progressive supranuclear palsy (PSP), a rapidly progressing neurodegenerative disorder associated with Tau dysfunction. In the future, development plans for the drug could extend to other Tauopathies such as frontotemporal dementia and Alzheimer’s disease.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail